The Board of Directors of IRLAB has appointed its current CEO, Nicholas Waters, to the role of Executive Vice President and Head of Research & Development and recruited Richard Godfrey as the new CEO.
“With the new management structure and the recruitment of Richard Godfrey, we are strengthening our resources and expertise in both the commercial and scientific disciplines. I now look forward to concentrating on leading the efforts to advance our current clinical drug projects towards the market and to generate further drug candidates using our unique AI-based research platform,” commented Nicholas Waters, IRLAB’s current CEO and future Executive Vice President and Head of Research & Development, in the company’s press release.
Both took up their new positions on 1 July.
Richard Godfrey, b. 1966, has over 25 years experience of leadership positions in the life science industry in the USA, the Nordic countries and the United Kingdom. He was CEO of the listed biotech company BerGenBio ASA for 12 years and most recently the Chief Operating Officer at LifeArc, a medical research foundations in the UK with an investment portfolio valued at close to 15 billion SEK. Richard Godfrey holds a bachelor’s degree in pharmaceutical chemistry from the University of Liverpool, an MBA from the University of Bath and is a member of The Royal Pharmaceutical Society of Great Britain.
“I am most impressed by the deep profound scientific insight, innovation and productivity of IRLAB’s drug discovery platform, ISP. The recent license agreement with Ipsen is a clear commercial validation of the company’s ability to develop novel drug candidates that offer meaningful patient benefits with significant commercial value. Now I look forward to working closely with Nicholas Waters and the highly competent team to establish IRLAB as a leading global biotech company developing novel drugs for patients with CNS disorders,” says Richard Godfrey, CEO of IRLAB, in the company’s press release.
Photo of Richard Godfrey: Nils Olav Mevatne